Case Report
Adrenal Incidentalomas with Supraphysiologic Response to ACTH Stimulus: A Case Report

Marianna Antonopoulou¹ and Asya Perelstein²

¹ SUNY Downstate Medical Center, 450 Clarkson Avenue, Box 1205, Brooklyn, NY 11203, USA
² VA Medical Center, 800 Poly Place, New York, NY 11209, USA

Correspondence should be addressed to Marianna Antonopoulou, marianitaki@gmail.com

Received 7 August 2012; Accepted 20 September 2012

1. Introduction
Adrenal incidentalomas are very common nowadays, and subclinical autonomous cortisol hypersecretion is the most frequent hormonal abnormality and it may be intermittent. This is why there is a need for periodic hormonal and morphological evaluation for several years [1]. Also, there is evidence that patients with subclinical Cushing’s syndrome (SCS) have increased cardiovascular risk profile, similar to that described in overt Cushing’s syndrome (CS), making the diagnosis of SCS of great importance [2]. We present the diagnostic approach of a patient with bilateral adrenal incidentalomas.

2. Case Report
2.1. History of Present Illness. The patient is a 72-year-old African-American male. After complaining of chronic back pain in 9/2009, he had a spine MRI that revealed arachnoiditis and prominence of bilateral adrenals. CT scan of abdomen/pelvis was done to further evaluate the adrenals that revealed lipid-rich adrenal masses bilaterally, right adrenal mass 5 × 3.5 cm, and left adrenal 3.7 × 2.9 cm (Figure 1). Both the masses were less than 20 Hounsfield units after contrast injection.

Besides his chronic back pain, the patient had no other complaints. He was very adherent to his medication although his blood pressure on occasion was ranging from 150/78 to 160/96. His medications include diltiazem 240 mg daily, lisinopril 10 mg daily, omeprazole 20 mg, aspirin 81 mg, plavix 75 mg, and tramadol 50 mg as needed for pain.

2.2. Past Medical History. It was hypertension, hyperlipidemia, spinal stenosis, monoclonal gammopathy of uncertain significance (MGUS), and coronary artery disease.
2.3. Social History. Patient was never a smoker. He rarely drank a glass of wine at social events and denied any use of illicit drugs or over-the-counter medication.

2.4. Family History. It was breast cancer and colon cancer in one sister and his father, respectively. His mother died of stroke and father of colon cancer.

2.5. Hospital Course. After the CT scan results, the patient was sent to our endocrine clinic for evaluation. On physical exam, the patient has no cushingoid features. He is slightly overweight, with BMI of 26 and no evidence of abnormal skin pigmentation, striae or evidence of proximal muscle weakness. He was screened for depression as part of the standard of care, and the patient health questionnaire (PHQ-9) was negative. He denied obstructive symptoms at night and admits waking up in the morning refreshed from the night sleep. Patient underwent hormonal workup to rule out cortisol-producing adrenal tumors three times, including 24-hour urine cortisol level, 24-hour urine metanephrines, serum aldosterone, and plasma renin activity (at that time patient was not on lisinopril), all of which were normal.

During followup, CT scans showed the adrenal masses remained stable in size, but the radiologist insisted that the CT findings are consistent with adrenal hyperplasia. In view of the patient also being hypertensive, he underwent an ACTH (cosyntropin) stimulation test to rule out late-onset CAH (congenital adrenal hyperplasia). In our case the patient’s cortisol went from baseline of 419 mmol/L to 1,848.53, 17-hydroxyprogesterone from 0.33 nmol/L to 11.69, and 11-deoxycortisol from 0.5772 mg/L to 10.97. ACTH at baseline was 1.034 pmol/L. CAH is unlikely in this case, since one would expect insufficient production of cortisol and a shift towards the precursors. Our patient had exaggerated response of both cortisol and the precursors. The patient subsequently underwent overnight 1 mg dexamethasone suppression test as screening for CS and also low dose (4 mg) suppression test. Patient failed both suppression tests with morning cortisol level of 215.2 mmol/L and 204.16 mmol/L, respectively. Normal response should be morning cortisol less than 49.662 mmol/L, according to the 2008 Endocrine Society Guidelines. The above results were consistent with SCS, most likely secondary to aberrant receptors. Thereafter, patient underwent workup to rule out the ectopic expression of glucose-dependent insulinoitropic peptide (GIP) receptor in zona fasciculata cells.

The postdexamethasone suppression test baseline fasting cortisol level was 215 mmol/L and 2-hours after a mixed meal was 201, essentially ruling out GIP-dependent CS. The full workup for aberrant receptors could not be performed because TRH and GnRH are not available in the USA and the patient started developing chest discomfort, had a positive stress test, and underwent coronary artery catheterization with stenting. The patient is currently recovering well.

3. Discussion

ACTH (adrenocorticotropic hormone) stimulation test is traditionally used in the diagnosis of adrenal insufficiency and also to diagnose cases of CAH. In CAH where 21-hydroxylase or 11-beta hydroxylase deficiency is common, the ACTH stimulation shifts the steroidogenesis to the precursors (Figure 2).

So 17-hydroxyprogesterone concentrations range typically from 10 to 100 nmol/L. Cortisol in healthy individuals should double from baseline and usually ranges from 386.26 to 689.75 mmol/L.

Abnormal response to ACTH stimulation test has been shown in patients with major depression [3]. Also, dysregulation of cortisol production is seen in patients with obstructive sleep apnea, obese patients, or with significant alcohol intake [4–7]. All of the above were excluded in our patient. Also, after careful review of the patient’s medication list, no medication was identified that would justify this response.

As supported by the literature search, supraphysiologic response of cortisol to ACTH stimulus occurs with ACTH-independent CS, also known as ACTH-independent macronodular adrenal hyperplasia (AIMAH). It is ACTH independent because endogenous ACTH levels are low or
normal, and cortisol secretion is regulated by hormones other than ACTH via aberrant expression of hormone receptors, like β-adrenergic, vasopressin, LH, FSH, TSH, and GIP receptors in the adrenals.

AIMAH accounts for <1% of overt CS. It usually presents in the 5th-6th decade of life as subclinical CS. It can be sporadic or familial (autosomal dominant). Supraphysiologic response of cortisol to ACTH occurs with AIMAH because the ACTH receptor gene remains expressed. However, there is also relatively inefficient hormonal synthesis with decreased expression of steroidalogenic enzymes. The hormone secretion in AIMAH results from an increase in the number of adrenocortical cells rather than an augmented synthesis per cell and this is why steroid precursors may be found elevated [8–13].

Diagnosis of subclinical CS is very challenging and currently there are no guidelines. However, according to some authors, the presence of at least two of the following: abnormal 1 mg dexamethasone suppression test, elevated 24 hr urine cortisol, ACTH below 2.2 pmol/L, constitutes diagnosis [14]. The adrenal glands are usually nodular but cases without nodules have also been described [15].

Unfortunately, the workup for aberrant receptors, to confirm ACTH-independent macronodular adrenal hyperplasia, is very tedious and some of the suggested stimuli like TRH or GnRH are not commercially available in the USA. Thus, we were unable to perform the protocol on our patient, but the workup for subclinical Cushing’s syndrome was positive and the abnormal response to ACTH stimulation test is suggestive of our diagnosis. The identification of aberrant receptors provides new opportunities in pharmacological therapy as an alternative to adrenalectomy. The patient had negative workup for GIP receptor, but in view of his CAD, we can give a trial of β-blocker in case his aberrant receptors are β-adrenergic [16]. There is still no consensus for the management of subclinical CS. However, according to one small study it appeared that surgical adrenalectomy was more beneficial than medical management as it improved the possible metabolic consequences like diabetes and hypertension, which are important risk factors for increased morbidity and mortality [2, 17].

Another consideration arises because of the patient’s previous diagnosis of MGUS. Thus far, in the literature there have been 3 cases of extramedullary plasmacytoma arising from the adrenals. One was actually bilateral and one was a functioning tumor secreting catecholamines [18–20]. Of course in our patient the tumor size has been stable for the past 2 years and urine was negative for Bence Jones protein, leading us away from a diagnosis of malignancy. The only way though to reach a certain diagnosis is through histologic examination. Unfortunately in this case, the patient’s comorbidities and recent cardiac procedure defer surgery, which would have been diagnostic and curative in the case of either functioning plasmacytoma or ACTH-independent adrenal hyperplasia with subclinical CS. It lies in the clinician’s judgment to make those difficult decisions.

4. Conclusions

Subclinical Cushing’s syndrome can be a cause of increased morbidity and mortality and the physician should be vigilant to diagnose and treat when appropriate. Since there is no consensus currently it relies on the clinician’s judgment how to manage these challenging cases.

References

[1] E. Vassilatou, A. Vryonidou, S. Michalopoulou et al., “Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study,” Clinical Endocrinology, vol. 70, no. 5, pp. 674–679, 2009.
[2] L. Tauchmanová, R. Rossi, B. Biondi et al., “Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 11, pp. 4872–4878, 2002.
[3] J. D. Amsterdam, A. Winokur, E. Abelman, I. Lucki, and K. Rickels, “Cosyntropin (ACTH a1-24) stimulation test in depressed patients and healthy subjects,” American Journal of Psychiatry, vol. 140, no. 7, pp. 907–909, 1983.
[4] M. Terzolo, S. Bovio, G. Reimondo et al., “Subclinical Cushing’s syndrome in adrenal incidentalomas,” Endocrinology and Metabolism Clinics of North America, vol. 34, no. 2, pp. 423–439, 2005.
[5] L. K. Nieman, B. M. Biller, J. W. Findling et al., “The diagnosis of Cushing’s syndrome: an endocrine society, clinical practice guideline,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 93, no. 5, pp. 1526–1540, 2008.

[6] D. W. Hudgel, E. A. Gordon, and H. Y. Meltzer, “Abnormal serotonergic stimulation of cortisol production in obstructive sleep apnea,” *American Journal of Respiratory and Critical Care Medicine*, vol. 152, no. 1, pp. 186–192, 1995.

[7] F. Besemer, A. M. Pereira, and J. W. A. Smit, “Alcohol-induced Cushing syndrome: hypercortisolism caused by alcohol abuse,” *Netherlands Journal of Medicine*, vol. 69, no. 7, pp. 318–323, 2011.

[8] A. Lacroix and I. Bourdeau, “Bilateral adrenal Cushing’s syndrome: macronodular adrenal hyperplasia and primary pigmented nodular adrenocortical disease,” *Endocrinology and Metabolism Clinics of North America*, vol. 34, no. 2, pp. 441–458, 2005.

[9] A. Lacroix, N. N’Diaye, J. Tremblay, and P. Hamet, “Ectopic and abnormal hormone receptors in adrenal Cushing’s syndrome,” *Endocrine Reviews*, vol. 22, no. 1, pp. 75–110, 2001.

[10] H. P. Hsiao, L. S. Kirschner, I. Bourdeau et al., “Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropic hormone-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors,” *Journal of Clinical Endocrinology and Metabolism*, vol. 94, no. 8, pp. 2930–2937, 2009.

[11] I. Bourdeau, P. D’Amour, P. Hamet, J. M. Boutin, and A. Lacroix, “Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing’s syndrome,” *Journal of Clinical Endocrinology and Metabolism*, vol. 86, no. 11, pp. 5534–5540, 2001.

[12] S. R. Antonini, V. Baldacchino, J. Tremblay, P. Hamet, and A. Lacroix, “Expression of ACTH receptor pathway genes in glucose-dependent insulinotropic peptide (GIP)-dependent Cushing’s syndrome,” *Clinical Endocrinology*, vol. 64, no. 1, pp. 29–36, 2006.

[13] M. Aiba, A. Hirayama, H. Iri et al., “Adrenocorticotropic hormone independent bilateral adrenocortical macronodular hyperplasia as a distinct subtype of Cushing’s syndrome. Enzyme histochemical and ultrastructural study of four cases with a review of literature,” *American Journal of Clinical Pathology*, vol. 96, pp. 334–340, 1991.

[14] I. Chiodini, “Diagnosis and treatment of subclinical hypercortisolism,” *Journal of Clinical Endocrinology and Metabolism*, vol. 96, no. 5, pp. 1223–1236, 2011.

[15] J. L. Doppman, L. K. Nieman, W. D. Travis et al., “CT and MR imaging of massive macronodular adrenocortical disease: a rare cause of autonomous primary adrenal hypercortisolism,” *Journal of Computer Assisted Tomography*, vol. 15, no. 5, pp. 773–779, 1991.

[16] A. Lacroix, J. Tremblay, G. Rousseau, M. Bouvier, and P. Hamet, “Propranolol therapy for ectopic β-adrenergic receptors in adrenal Cushing’s syndrome,” *New England Journal of Medicine*, vol. 337, no. 20, pp. 1429–1434, 1997.

[17] A. Toniato, I. Merante-Boschin, G. Opocher, M. R. Pelizzo, F. Schiavi, and E. Ballotta, “Surgical versus conservative management for subclinical cushing syndrome in adrenal incidentalomas: a prospective randomized study,” *Annals of Surgery*, vol. 249, no. 3, pp. 388–391, 2009.

[18] Y. Li, Y. K. Guo, Z. G. Yang, E. S. Ma, and P. Q. Min, “Extramedullary plasmacytoma involving the bilateral adrenal glands on MR imaging,” *Korean Journal of Radiology*, vol. 8, no. 3, pp. 246–248, 2007.

[19] S. Fujikata, N. Tanji, K. Aoki, H. Ohoka, N. Hojo, and M. Yokoyama, “Extramedullary plasmacytoma arising from an adrenal gland,” *Urology*, vol. 60, no. 3, p. 514, 2002.

[20] T. Kahara, Y. Nagai, H. Yamashita, E. Nohara, K. Kobayashi, and T. Takamura, “Extramedullary plasmacytoma in the adrenal incidentaloma,” *Clinical Endocrinology*, vol. 55, no. 2, pp. 267–270, 2001.